JAMA neurologyPub Date : 2025-03-17DOI: 10.1001/jamaneurol.2025.0177
S Andrew Josephson
{"title":"JAMA Neurology-The Year in Review 2024.","authors":"S Andrew Josephson","doi":"10.1001/jamaneurol.2025.0177","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0177","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-17DOI: 10.1001/jamaneurol.2025.0086
Juntao Yin, Yuqing Wei, Lixin Guo
{"title":"Belly Dancer’s Dyskinesia Following Acute Corpus Callosum Infarction","authors":"Juntao Yin, Yuqing Wei, Lixin Guo","doi":"10.1001/jamaneurol.2025.0086","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0086","url":null,"abstract":"This case report describes a patient with spontaneous, arrhythmic, spasmodic contractions of the abdominal muscles whose imaging confirmed involvement of the genu, body, and splenium of the corpus callosum.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"16 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143635125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-17DOI: 10.1001/jamaneurol.2025.0137
Ravi Dhawan, Alex B Boyle, Hithardhi Duggireddy, Margherita Rampichini, Denys Shay
{"title":"Venture Capital Investment in Neurology Companies.","authors":"Ravi Dhawan, Alex B Boyle, Hithardhi Duggireddy, Margherita Rampichini, Denys Shay","doi":"10.1001/jamaneurol.2025.0137","DOIUrl":"10.1001/jamaneurol.2025.0137","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-10DOI: 10.1001/jamaneurol.2025.0051
Rachel Grashow, Douglas P Terry, Aaron L Baggish
{"title":"Health Information Seeking-CTE Perception and Suicide-Reply.","authors":"Rachel Grashow, Douglas P Terry, Aaron L Baggish","doi":"10.1001/jamaneurol.2025.0051","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0051","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-10DOI: 10.1001/jamaneurol.2025.0058
He Li, Yang Cheng, Wei Tang
{"title":"Cerebral White Matter Abnormality Features of Encephalitis Caused by Angiostrongylus cantonensis.","authors":"He Li, Yang Cheng, Wei Tang","doi":"10.1001/jamaneurol.2025.0058","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0058","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-10DOI: 10.1001/jamaneurol.2025.0065
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, Ming Lu, JonDavid Sparks, Scott Andersen, Steve Lauzon, Emel Serap Monkul Nery, Chakib Battioui, Staci E Engle, Alessandro Biffi, Diana Svaldi, Stephen Salloway, Steven M Greenberg, Reisa A Sperling, Mark Mintun, Dawn A Brooks, John R Sims
{"title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.","authors":"Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, Ming Lu, JonDavid Sparks, Scott Andersen, Steve Lauzon, Emel Serap Monkul Nery, Chakib Battioui, Staci E Engle, Alessandro Biffi, Diana Svaldi, Stephen Salloway, Steven M Greenberg, Reisa A Sperling, Mark Mintun, Dawn A Brooks, John R Sims","doi":"10.1001/jamaneurol.2025.0065","DOIUrl":"10.1001/jamaneurol.2025.0065","url":null,"abstract":"<p><strong>Importance: </strong>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.</p><p><strong>Objective: </strong>To characterize ARIA in participants treated with donanemab.</p><p><strong>Design, setting, and participants: </strong>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controlled trials and the open-label addendum aged 60 to 85 years with early symptomatic Alzheimer disease and elevated amyloid levels were included. The placebo-controlled trials, but not the addendum, had tau inclusion criteria.</p><p><strong>Interventions: </strong>Placebo-controlled trial participants were randomized 1:1 to receive placebo or donanemab, and all open-label participants received donanemab. Donanemab was administered every 4 weeks for up to 72 weeks.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were the frequency, radiographic severity, seriousness, symptoms, timing relative to donanemab treatment, and risk factors for ARIA.</p><p><strong>Results: </strong>Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female. Frequencies of ARIA-edema/effusions (ARIA-E) and ARIA-microhemorrhages and hemosiderin deposition (ARIA-H) were higher with donanemab (24.4% and 31.3% in placebo-controlled trials, respectively; 19.8% and 27.2% in open-label addendum, respectively) than with placebo (1.9% and 13.0%, respectively). ARIA-E was mostly mild or moderate in severity. Serious ARIA-E was reported in 1.5% and symptomatic ARIA-E in 5.8% of donanemab-treated participants in the placebo-controlled trials. Symptoms most frequently reported with ARIA-E were headache and confusional state. In 58.3% of donanemab-treated participants with ARIA-E, the first event occurred by the third infusion (approximately month 3). Risk analysis demonstrated independent associations between ARIA-E and 6 baseline variables, including increased risk with APOE ε4 allele number, greater number of microhemorrhages, presence of cortical superficial siderosis, higher amyloid plaque, and elevated mean arterial pressure, and decreased risk with antihypertensive use.</p><p><strong>Conclusions and relevance: </strong>ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. Individual ARIA risk can","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-03DOI: 10.1001/jamaneurol.2025.0008
Ruben Jauregui, Kevin M. Spiegler, Nina Kim
{"title":"Chronic Neuropsychiatric Sequelae Associated With Kambo Intoxication","authors":"Ruben Jauregui, Kevin M. Spiegler, Nina Kim","doi":"10.1001/jamaneurol.2025.0008","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0008","url":null,"abstract":"This case report describes a 35-year-old female patient experiencing chronic neuropsychiatric symptoms related to <jats:italic>kambo</jats:italic>, a secretion of the South American giant leaf frog, and noted abnormalities on initial magnetic resonance imaging with subsequent resolution.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"1 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA neurologyPub Date : 2025-03-03DOI: 10.1001/jamaneurol.2025.0001
Brian C. Callaghan, Evan L. Reynolds, Lavanya Muthukumar, Melissa A. Elafros, Lesli E. Skolarus, James F. Burke, Kevin A. Kerber
{"title":"Diagnostic Testing for Patients With Peripheral Neuropathy","authors":"Brian C. Callaghan, Evan L. Reynolds, Lavanya Muthukumar, Melissa A. Elafros, Lesli E. Skolarus, James F. Burke, Kevin A. Kerber","doi":"10.1001/jamaneurol.2025.0001","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0001","url":null,"abstract":"This cross-sectional study compares the diagnostic testing for patients with peripheral neuropathy of patients from 1998 to 2007 with patients in 2019.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"84 5 Pt 1 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}